肿瘤细胞治疗研究
英文原题：Novel therapeutic strategies for ccRCC through integration of systemic drug combinations and oncolytic adenovirus immunotherapy.
Novel therapeutic strategies for ccRCC through integration of systemic drug combinations and oncolytic adenovirus immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
这些发现表明，将靶向治疗与溶瘤病毒治疗相结合，有望克服 ccRCC 当前的治疗局限。此外，使用先进的三维人源相关 PDC 模型提供了一个可扩展的平台，用于评估联合治疗、支持个性化治疗策略，并促进适用于 ccRCC 及其他癌症类型的治疗方法的开发。
透明细胞肾细胞癌（ccRCC）因其生物学异质性、临床行为多变以及单药系统性治疗疗效有限，仍是一项重大的治疗挑战。靶向多条肿瘤促进通路的联合策略可能改善治疗结局。
我们使用代表性的患者来源癌细胞（PDC）模型，评估了将靶向系统性药物与溶瘤腺病毒治疗相结合的联合治疗策略。通过评估抗肿瘤疗效和免疫介导的细胞毒性，研究了不同患者来源模型的治疗反应。
联合治疗相比任一单药治疗增强了抗肿瘤活性，并促进了涉及CD8+ T细胞和自然杀伤（NK）细胞的免疫介导的细胞毒性。三种PDC模型的治疗反应各不相同，反映了患者间异质性，并提示生物标志物指导的患者分层具有潜在价值。
We evaluated combination treatment strategies integrating targeted systemic drugs with oncolytic adenovirus therapy using representative patient-derived cancer cell (PDC) models. Anti-tumor efficacy and immune-mediated cytotoxicity were assessed to investigate treatment responses across different patient-derived models.
Combination treatment enhanced anti-tumor activity compared with either monotherapy alone and promoted immune-mediated cytotoxicity involving CD8+ T cells and natural killer (NK) cells. Treatment responses varied across the three PDC models, reflecting interpatient heterogeneity and suggesting potential value for biomarker-guided patient stratification. DISCUSSION: These findings demonstrate the potential of combining targeted therapy with oncolytic virotherapy to overcome current therapeutic limitations in ccRCC. Moreover, the use of advanced three-dimensional human-relevant PDC models provides a scalable platform for evaluating combination therapies, supporting personalized treatment strategies, and facilitating the development of therapeutic approaches applicable to ccRCC and other cancer types.
MEMBER ACCOUNT
登录成功会直接打开下一页。
